Regeneron Pharmaceuticals (REGN) Gross Margin (2009 - 2026)

Regeneron Pharmaceuticals' Gross Margin history runs 18 years deep, the most recent figure standing at 91.59% for Q2 2026.

• In Q2 2026, Gross Margin fell 91.0% year-over-year to 91.59%; the TTM figure through Jun 2026 stood at 91.41% (down 63.0% YoY), while the FY2025 annual figure was 92.05%, down 30.0% from the prior year.
• Gross Margin for Q2 2026 stood at 91.59%, up from 89.64% in the prior quarter.
• The five-year high for Gross Margin was 94.78% in Q2 2022, with the low at 314.6% in Q1 2022.
• The 5-year median for Gross Margin is 92.41% (2023), against an average of 54.78%.
• The sharpest annual moves came in 2022 and 2023: Gross Margin sank 40736 bps in 2022, then jumped 40672 bps in 2023.
• Regeneron Pharmaceuticals' Gross Margin stood at 178.0% in 2022, then jumped by 152 bps to 92.47% in 2023, then retreated by 1 bps to 91.38% in 2024, then gained by 0 bps to 91.8% in 2025, then decreased by 0 bps to 91.59% in 2026.
• Business Quant data shows REGN's Gross Margin at 91.59% in Q2 2026, 89.64% in Q1 2026, and 91.8% in Q4 2025.